comparemela.com

Latest Breaking News On - Society of urologic oncology - Page 1 : comparemela.com

ASCO 2024: Treatment Outcomes for Patients with Ga68-PSMA-PET Prostate Cancer with or Without Conventional Imaging Correlates

ASCO 2024, Prostate Cancer, metastatic hormone-sensitive prostate cancer (mHSPC), Ga68-PSMA-PET, EA8191/INDICATE (NCT04423211).

Toronto
Ontario
Canada
Chicago
Illinois
United-states
Dallas
Texas
University-of-texas
American
Wadih-issa
Julian-chavarriaga

ASCO 2024: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-304 Study

ASCO 2024 phase III STELLAR-304 trial, combination of zanzalintinib (XL092) plus nivolumab in patients with non-clear cell renal cell carcinoma (nccRCC), tyrosine kinase inhibitor (TKI) sunitinib.

Toronto
Ontario
Canada
United-states
Chicago
Illinois
American
America
Sumantak-pal
Sumanta-pal
American-society-of-clinical-oncology
Twitter

ASCO 2024: ADT Sparing Approaches in the Metastatic Hormone-Sensitive and Castrate-Resistant Spaces

discussed ADT-sparing approaches in both the metastatic castrate sensitive and resistant settings.

United-states
New-york
Toronto
Ontario
Canada
Chicago
Illinois
Crawford
Memorial-sloan-kettering-cancer-center
American
Karen-autio
Karena-autio

ASCO 2024: Belzutifan in Patients with Advanced Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 2 LITESPARK-013 Study

ASCO 2024, advanced clear cell renal cell carcinoma (ccRCC), Belzutifan, LITESPARK-013 Study, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).

United-states
Toronto
Ontario
Canada
Washington
Georgetown-university
District-of-columbia
Chicago
Illinois
American
Michael-atkins
Michaelb-atkins

ASCO 2024: A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03)

ASCO 2024 results of a multicenter phase II trial of modified FOLFIRINOX for the first-line treatment of advanced urachal cancer (ULTMA; KCSG GU20-03), Urachal cancer is a rare malignancy accounting for 1% of bladder cancers.

Chicago
Illinois
United-states
Toronto
Ontario
Canada
South-korea
Seoul
Soult-ukpyolsi
American
Jae-lyun-lee
Md-anderson-cancer-center

vimarsana © 2020. All Rights Reserved.